AMA launches new telehealth initiative

The new effort, Return on Health, will provide a framework to ensure the value of digitally enabled care models is understood and established. The initiative comes at a time when telehealth has taken off since the start of the COVID-19 pandemic. The U.S. healthcare system has become more accepting of virtual visits since the pandemic, after in-person care posed more risks for exposure to the virus. However, not all the benefits of virtual care are fully understood, according to the AMA.

The Return on Health framework, which was developed by the AMA and Manatt Health with input from healthcare experts, accounts for the various ways virtual care programs increase the “return on health” with positive impacts for patients, clinicians, payers and society. Specifically, the program aims to “move beyond dollars in cents” when assessing the value of virtual care.

“Understanding the value of virtual care is vital to inform decision making that facilitates the shift to digitally enabled care models that blend the best features of in-person care with those of virtual care,” AMA Board Member Jack Resneck Jr., MD, said in a statement. “The AMA’s framework fills a critical need to inclusively define and measure the various benefits generated by virtual care as decision makers design new care models, prioritize investments and determine appropriate coverage and payment policies in the future."

The framework includes the benefits of virtual care along six value streams: clinical outcome; quality and safety; access to care; patient and family experience; clinician experience; financial and operational impact; and health equity. In addition, the framework incorporates the six value streams of the environmental variables: practice type, payment arrangements, patient population, clinical use case, and virtual care modality.

The AMA is using real-world case studies with the early adopters of the digitally enabled hybrid model to demonstrate the use of the framework and how more healthcare stakeholders can realize the full potential of virtual care.

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.